Skip to main navigation
About Us
Our Core Values
Senior Management
Board of Directors
Collaborations
Products
MARGENZA™
Pipeline
Margetuximab (HER2)
Flotetuzumab (CD123 x CD3)
Retifanlimab (PD-1)
Tebotelimab (PD-1 x LAG-3)
MGD019 (PD-1 x CTLA-4)
Enoblituzumab (B7-H3)
MGC018 (B7-H3)
MGD014 (HIV x CD3)
Platforms
DART® and TRIDENT®
Fc Optimization
Patients
Investors
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Senior Management
Board of Directors
Committee Composition
Contact the Board
Financials & Filings
SEC Filings
Quarterly Results
Key Metrics
Stock Information
Historic Stock Lookup
Investment Calculator
Analyst Coverage
Ownership Profile
Investor FAQs
Publications
Contact Us
Careers
Current Openings
Employee Benefits
Shareholder Tools
Facebook
LinkedIn
Twitter
RSS
Breadcrumb
Home
Investors
Email Alerts - Unsubscribe
Unsubscribe from all MacroGenics, Inc. email alerts
Email Address
Leave this field blank
